Aastrom (ASTM) Manufacturing Transfer and CLI Product Naming
Long/Short Equity, Special Situations, Contrarian
Seeking Alpha Analyst Since 2009
Manufacturing steps completed in preparation for PIII CLI Program
ASTM transferred cell cassette manufacturing to ATEK Medical under the 10/10 partnership. These single-use cell cassettes are the central component used in its proprietary culturing process at its cell manufacturing facility. Ixmyelocel-T has been formally accepted by the US FDA and the Adopted Names Council as the non-proprietary name for ASTM’s investigational cell therapy product.
The Bottom Line: Packaged noise, not milestones but, Needham & Co’s “BUY” and $6.00 price target stimulated share appreciation. However, recognize this is the press build-up pre one SPA approval which will substantiate a … very … dilutionary offering by Needham and Stifel. Needham also came out with a “BUY” on Pluristem (PSTI), ASTM’s comparable at $5.00. Just, keeping the banking fee “pot” warm!
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.